Literature DB >> 21784453

Spectrum of mutations in Noonan syndrome and their correlation with phenotypes.

Beom Hee Lee1, Jae-Min Kim, Hye Young Jin, Gu-Hwan Kim, Jin-Ho Choi, Han-Wook Yoo.   

Abstract

OBJECTIVES: To investigate mutation spectrums and their correlations to phenotypes in Noonan syndrome (NS) and NS-related disorders that share functional alterations of the Ras-mitogen-activated protein kinase pathway. STUDY
DESIGN: Clinical characteristics and genotypes of 10 previously known and 2 candidate genes, SPRY1-4 and SPRED1, were investigated in 59 patients with NS, 17 with cardiofaciocutaneous syndrome, 5 with Costello syndrome, and 2 with LEOPARD syndrome.
RESULTS: PTPN11 (39.0%), SOS1 (20.3%), RAF1 (6.8%), KRAS (5.1%), and BRAF (1.7%) mutations were identified in NS; BRAF (41.2%), SHOC2 (23.5%), and MEK1 (5.9%) mutations in cardiofaciocutaneous syndrome; and HRAS and PTPN11 mutations in Costello syndrome and LEOPARD syndrome, respectively. No additional mutations were identified in 28.9% of NS and 35.3% of cardiofaciocutaneous syndrome. Functional characterizations of 2 RAF1 novel variants, p.P261T and p.S259T, and one SOS1 variant, p.K170E, showed enhanced activity of Ras-mitogen-activated protein kinase pathway. Normal stature was frequent in SOS1 mutations, hypertrophic cardiomyopathy in RAF1, and developmental delay in RAF1, BRAF, or SHOC2 mutations.
CONCLUSIONS: By identifying genotype-phenotype correlations, our study highlights the role of molecular genetic testing in the process of differential diagnosis of NS and NS-related disorders. Pathophysiologies that underlie these correlations are needed to be investigated in terms of their effects on Ras-mitogen-activated protein kinase pathway.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21784453     DOI: 10.1016/j.jpeds.2011.05.024

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  29 in total

1.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

2.  The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach.

Authors:  Bruce Korf; Reza Ahmadian; Judith Allanson; Yoko Aoki; Annette Bakker; Emma Burkitt Wright; Brian Denger; Ype Elgersma; Bruce D Gelb; Karen W Gripp; Bronwyn Kerr; Maria Kontaridis; Conxi Lazaro; Corinne Linardic; Reymundo Lozano; Calum A MacRae; Ludwine Messiaen; Sonia Mulero-Navarro; Benjamin Neel; Scott Plotkin; Katherine A Rauen; Amy Roberts; Alcino J Silva; Sitta G Sittampalam; Chao Zhang; Lisa Schoyer
Journal:  Am J Med Genet A       Date:  2015-04-21       Impact factor: 2.802

3.  Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.

Authors:  Hélène Cavé; Aurélie Caye; Nehla Ghedira; Yline Capri; Nathalie Pouvreau; Natacha Fillot; Aurélien Trimouille; Cédric Vignal; Odile Fenneteau; Yves Alembik; Jean-Luc Alessandri; Patricia Blanchet; Odile Boute; Patrice Bouvagnet; Albert David; Anne Dieux Coeslier; Bérénice Doray; Olivier Dulac; Valérie Drouin-Garraud; Marion Gérard; Delphine Héron; Bertrand Isidor; Didier Lacombe; Stanislas Lyonnet; Laurence Perrin; Marlène Rio; Joëlle Roume; Sylvie Sauvion; Annick Toutain; Catherine Vincent-Delorme; Marjorie Willems; Clarisse Baumann; Alain Verloes
Journal:  Eur J Hum Genet       Date:  2016-01-13       Impact factor: 4.246

Review 4.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

Review 5.  Short and tall stature: a new paradigm emerges.

Authors:  Jeffrey Baron; Lars Sävendahl; Francesco De Luca; Andrew Dauber; Moshe Phillip; Jan M Wit; Ola Nilsson
Journal:  Nat Rev Endocrinol       Date:  2015-10-06       Impact factor: 43.330

6.  Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.

Authors:  Andrew R Grant; Brandon J Cushman; Hélène Cavé; Mitchell W Dillon; Bruce D Gelb; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Marco Tartaglia; Lisa M Vincent; Martin Zenker
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

7.  Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Authors:  Keyur P Patel; Kate J Newberry; Rajyalakshmi Luthra; Elias Jabbour; Sherry Pierce; Jorge Cortes; Rajesh Singh; Meenakshi Mehrotra; Mark J Routbort; Madan Luthra; Taghi Manshouri; Fabio P Santos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

8.  Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies.

Authors:  Won Kyoung Jhang; Jin-Ho Choi; Beom Hee Lee; Gu-Hwan Kim; Han-Wook Yoo
Journal:  Pediatr Cardiol       Date:  2016-08-23       Impact factor: 1.655

9.  Noonan syndrome in diverse populations.

Authors:  Paul Kruszka; Antonio R Porras; Yonit A Addissie; Angélica Moresco; Sofia Medrano; Gary T K Mok; Gordon K C Leung; Cedrik Tekendo-Ngongang; Annette Uwineza; Meow-Keong Thong; Premala Muthukumarasamy; Engela Honey; Ekanem N Ekure; Ogochukwu J Sokunbi; Nnenna Kalu; Kelly L Jones; Julie D Kaplan; Omar A Abdul-Rahman; Lisa M Vincent; Amber Love; Khadija Belhassan; Karim Ouldim; Ihssane El Bouchikhi; Anju Shukla; Katta M Girisha; Siddaramappa J Patil; Nirmala D Sirisena; Vajira H W Dissanayake; C Sampath Paththinige; Rupesh Mishra; Eva Klein-Zighelboim; Bertha E Gallardo Jugo; Miguel Chávez Pastor; Hugo H Abarca-Barriga; Steven A Skinner; Eloise J Prijoles; Eben Badoe; Ashleigh D Gill; Vorasuk Shotelersuk; Patroula Smpokou; Monisha S Kisling; Carlos R Ferreira; Leon Mutesa; Andre Megarbane; Antonie D Kline; Amy Kimball; Emmy Okello; Peter Lwabi; Twalib Aliku; Emmanuel Tenywa; Nonglak Boonchooduang; Pranoot Tanpaiboon; Antonio Richieri-Costa; Ambroise Wonkam; Brian H Y Chung; Roger E Stevenson; Marshall Summar; Kausik Mandal; Shubha R Phadke; María G Obregon; Marius G Linguraru; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2017-07-27       Impact factor: 2.802

10.  RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome.

Authors:  Nina Bögershausen; I-Chun Tsai; Esther Pohl; Pelin Özlem Simsek Kiper; Filippo Beleggia; E Ferda Percin; Katharina Keupp; Angela Matchan; Esther Milz; Yasemin Alanay; Hülya Kayserili; Yicheng Liu; Siddharth Banka; Andrea Kranz; Martin Zenker; Dagmar Wieczorek; Nursel Elcioglu; Paolo Prontera; Stanislas Lyonnet; Thomas Meitinger; A Francis Stewart; Dian Donnai; Tim M Strom; Koray Boduroglu; Gökhan Yigit; Yun Li; Nicholas Katsanis; Bernd Wollnik
Journal:  J Clin Invest       Date:  2015-08-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.